Close

More on ALXN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (3.4 Score)
- Holders
- Event Driven Deals
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- M&A (6/30/20 *Est)
- M&A (9/30/21 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

ALXN Balance Sheet

Click line-items for a historical chart and %
Assets
Cash and cash equivalents 597.55M
Marketable securities 582.5M
Trade accounts receivable, net 609.3M
Inventories 329.85M
Deferred tax assets
Prepaid expenses and other current assets 242.01M
Total current assets 2.36B
Property, plant and equipment, net 825.3M
Intangible assets, net 4.55B
Goodwill 5.04B
Deferred tax assets
Other assets 257.63M
Total assets 13.03B
Liabilities and Stockholders' Equity
Accounts payable 28.98M
Accrued expenses 407.29M
Deferred revenue 53.42M
Current portion of convertible notes
Current portion of capital lease obligations
Other current liabilities 89.64M
Total current liabilities 658.46M
Capital lease obligations, less current portion
Convertible notes, less current portion
Deferred tax liabilities 570.07M
Contingent consideration
Other liabilities 124.38M
Total liabilities 4.83B
Commitments and contingencies (Note 16)
Stockholders' Equity:
Preferred stock, $0.0001 par value; 5,000 shares authorized, no shares issued or outstanding
Common stock, $0.0001 par value; 290,000 shares authorized; 184,219 and 182,471 shares issued at June 30, 2011 and December 31, 2010, respectively 23K
Additional paid-in capital 7.85B
Treasury stock, at cost -1.04B
Accumulated other comprehensive loss 694K
Accumulated deficit 1.39B
Total stockholders' equity 8.2B
Total liabilities and stockholders' equity 13.03B